bluebird bio (Nasdaq:BLUE) - 주가, 뉴스 및 분석

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

BLUE 주식 개요

는 미국에서 중증 유전 질환 치료를 위한 유전자 치료제를 연구, 개발 및 상용화하는 생명공학 회사입니다.

BLUE 기본 분석
눈송이 점수
가치 평가	5/6
미래 성장	2/6
과거 실적	0/6
재무 상태	2/6
배당금	0/6

보상

공정 가치 추정치보다 낮은 87.3% 에서 거래

수익은 연간 40.44% 증가할 것으로 예상됩니다.

동종업계 및 업계 대비 좋은 가치로 거래

위험 분석

지난 1년 동안 주주가 크게 희석되었습니다.

cash runway 경력이 1년 미만입니다.

현재 수익성이 없으며 향후 3년 동안 수익을 낼 것으로 예상되지 않습니다.

의미 있는 시가총액이 없습니다. ( $97M )

+ 1 더 많은 위험

bluebird bio, Inc. 경쟁사

Generation Bio

NasdaqGS:GBIO

US$162.2m

Fennec Pharmaceuticals

NasdaqCM:FENC

US$142.3m

Connect Biopharma Holdings

NasdaqGM:CNTB

US$74.6m

Kronos Bio

NasdaqGS:KRON

US$59.1m

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 bluebird bio
과거 주가
현재 주가	US$0.50
52주 최고치	US$5.53
52주 최저치	US$0.46
베타	0.80
11개월 변경	-10.17%
3개월 변경 사항	-48.28%
1년 변경 사항	-83.41%
33년 변화	-97.36%
5년 변화	-99.43%
IPO 이후 변화	-98.13%

최근 뉴스 및 업데이트

bluebird bio: Scientific Success And Financial Success, And The Gap Between

Sep 26

Recent updates

Here's Why We're A Bit Worried About bluebird bio's (NASDAQ:BLUE) Cash Burn Situation

Jul 13

Bluebird, Real Endpoints team up to increase access to pricey gene therapy Zynteglo

Oct 04

Bluebird bio names interim finance chief

Sep 26

Bluebird bio jumps 17% on FDA approval of new gene therapy

Sep 19

bluebird bio' chief strategy and financial officer to depart

Sep 12

FDA approves bluebird bio's Zyntego beti-cel gene therapy for beta thalassemia

Aug 17

bluebird bio: Potential For 3 Gene Therapy Approvals In 12 Months Makes Buy Case

Jun 22

bluebird bio: Beaten Down Biotech With Possible Long-Term Potential

May 09

Bluebird Bio: Gene Therapy Launches Could Bring Big Revenues, Providing They Meet Approval

Feb 07

주주 수익률

	BLUE	US Biotechs	US 마켓
7D	7.3%	-2.9%	0.9%
1Y	-83.4%	18.9%	32.3%

수익률 대 산업: BLUE 지난 1년 동안 15.3 %를 반환한 US Biotechs 업계보다 저조한 성과를 냈습니다.

수익률 대 시장: BLUE 지난 1년 동안 25.3 %를 반환한 US 시장보다 저조한 성과를 냈습니다.

가격 변동성

Is BLUE's price volatile compared to industry and market?
BLUE volatility
BLUE Average Weekly Movement	14.2%
Biotechs Industry Average Movement	10.0%
Market Average Movement	6.4%
10% most volatile stocks in US Market	14.8%
10% least volatile stocks in US Market	3.2%

안정적인 주가: BLUE 의 주가는 지난 3개월 동안 변동성이 심했습니다.

시간에 따른 변동성: BLUE 의 주간 변동성( 14% )은 지난 1년 동안 안정적이었지만 여전히 US 의 75%보다 높습니다. 주식.

회사 소개

설립	직원	CEO	웹사이트
1992	375	Andrew Obenshain	www.bluebirdbio.com

는 미국에서 중증 유전 질환 치료를 위한 유전자 치료제를 연구, 개발 및 상용화하는 생명공학 회사입니다. 이 회사의 중증 유전 질환 치료 제품 후보로는 수혈 의존성 지중해빈혈 치료제 진테글로(ZYNTEGLO, 베티베글로겐 오토템셀), 겸상 적혈구 질환(SCD) 치료제 로보티베글로겐 오토템셀, 뇌부신백질이영양증 치료제 스카이소나(스카이소나 엘리발도진 오토템셀) 등이 있습니다. 임상 개발 프로그램에는 SCD 환자 치료에서 로보셀의 안전성과 효능을 평가하기 위한 HGB-205, HGB-206 및 HGB-210과 지중해빈혈 환자 치료에서 베티셀의 안전성과 효능을 평가하기 위한 HGB-204, HGB-205, HGB-207 및 HGB-212가 있습니다.

bluebird bio, Inc. 기본 사항 요약

bluebird bio 의 수익과 매출은 시가총액과 어떻게 비교하나요?
BLUE 기본 통계
시가총액	US$97.81m
수익(TTM)	-US$319.25m
수익(TTM)	US$54.90m

1.8x

P/S 비율

-0.3x

P/E 비율

BLUE 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
BLUE 손익 계산서(TTM)
수익	US$54.90m
수익 비용	US$76.13m
총 이익	-US$21.23m
기타 비용	US$298.02m
수익	-US$319.25m

최근 보고된 수익

Jun 30, 2024

다음 수익 날짜

n/a

주당 순이익(EPS)	-1.65
총 마진	-38.67%
순이익 마진	-581.51%
부채/자본 비율	141.7%

BLUE 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

BLUE 주식 개요

보상

위험 분석

bluebird bio, Inc. 경쟁사

NasdaqGS:GBIO

US$162.2m

NasdaqCM:FENC

US$142.3m

NasdaqGM:CNTB

US$74.6m

NasdaqGS:KRON

US$59.1m

가격 내역 및 성능

최근 뉴스 및 업데이트

bluebird bio: Scientific Success And Financial Success, And The Gap Between

bluebird bio, Inc., Annual General Meeting, Nov 06, 2024

bluebird bio Announces Receipt of Expected Notices from Nasdaq Due to Non-Compliance with Nasdaq Listing Rule 5250(c)(1)

bluebird bio, Inc. Provides Revenue Guidance for the Third and Fourth Quarter of 2024

Price target decreased by 13% to US$3.67

Price target decreased by 11% to US$3.78

Recent updates

bluebird bio: Scientific Success And Financial Success, And The Gap Between

bluebird bio, Inc., Annual General Meeting, Nov 06, 2024

bluebird bio Announces Receipt of Expected Notices from Nasdaq Due to Non-Compliance with Nasdaq Listing Rule 5250(c)(1)

bluebird bio, Inc. Provides Revenue Guidance for the Third and Fourth Quarter of 2024

Price target decreased by 13% to US$3.67

Price target decreased by 11% to US$3.78

bluebird bio's Flight Through Financial Fog And Fierce Rivals

bluebird bio, Inc. Announces Chief Financial Officer Changes, Effective June 10, 2024

bluebird bio, Inc. announced delayed 10-Q filing

Bluebird Bio, Inc. Announces Completion of First Cell Collection for LYFGENIA Gene Therapy

Bragar Eagel & Squire, P.C. Files Class Action Lawsuit Against Bluebird Bio Inc

bluebird bio, Inc. announced delayed annual 10-K filing

bluebird bio Is Priced Below IP Value

Price target increased by 8.0% to US$5.00

Bluebird Bio: Innovative Therapies, Monetary Setbacks

bluebird bio, Inc. has completed a Follow-on Equity Offering in the amount of $125 million.

New major risk - Shareholder dilution

bluebird bio, Inc. has completed a Follow-on Equity Offering in the amount of $125 million.

bluebird bio, Inc. has filed a Follow-on Equity Offering in the amount of $150 million.

Consensus revenue estimates fall by 13%

Price target decreased by 8.2% to US$6.61

Bluebird Bio Inc. Presents Long-Term Data At Ash Support Beti-Ccel as A Potentially Curative Gene Therapy for -Thalassemia Patients Who Require Regular Transfusion Independence and Normal or Near- Normal- Normal- Normal-Normal Adult Hb Levels

Bluebird Bio Details Plans for the Commercial Launch of Lyfgenia(Tm) Gene Therapy for Patients Ages 12 and Older with Sickle Cell Disease and A History of Vaso-Occlusive Events

Now 31% undervalued after recent price drop

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

New major risk - Revenue and earnings growth

Bluebird Bio, Inc. to Present New and Updated Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 65th American Society of Hematology Annual Meeting and Exposition

Now 24% undervalued after recent price drop

bluebird bio, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Is bluebird bio (NASDAQ:BLUE) In A Good Position To Invest In Growth?

New minor risk - Insider selling

President recently sold US$60k worth of stock

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Here's Why We're A Bit Worried About bluebird bio's (NASDAQ:BLUE) Cash Burn Situation

bluebird bio, Inc. Announces FDA Priority Review of the Biologics License Application for Lovotibeglogene Autotemcel (Lovo-Cel) for Patients with Sickle Cell Disease (Scd) 12 Years and Older with a History of Vaso-Occlusive Events

Consensus revenue estimates decrease by 26%, EPS upgraded

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus forecasts updated

bluebird bio, Inc. Appoints Joseph Vittiglio, JD as Chief Business and Legal Officer

U.S. Food and Drug Administration Lifts Partial Clinical Hold for bluebird bio, Inc.’s Sickle Cell Disease Studies for Patients Under the Age of 18

Bluebird Bio, Inc. Presents New and Updated Data At the 64Th American Society of Hematology Annual Meeting and Exposition

An unknown buyer entered into a definitive agreement to acquire SKYSONA & ZYNTEGLO of bluebird bio, Inc. (NasdaqGS:BLUE) for approximately $100 million.

Consensus forecasts updated

Less than half of directors are independent

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

bluebird bio, Inc. Appoints Christopher Krawtschuk as Treasurer, Principal Financial Officer and Principal Accounting Officer

Bluebird, Real Endpoints team up to increase access to pricey gene therapy Zynteglo

Bluebird bio names interim finance chief

bluebird bio, Inc. Announces Executive Changes Effective October 14, 2022

Bluebird bio jumps 17% on FDA approval of new gene therapy

bluebird bio Receives FDA Accelerated Approval for SKYSONA® Gene Therapy for Early, Active Cerebral Adrenoleukodystrophy (CALD)

bluebird bio, Inc. Announces Executive Changes

bluebird bio' chief strategy and financial officer to depart

Treasurer recently sold US$78k worth of stock

Consensus forecasts updated

bluebird bio, Inc. Announces FDA Approval of Zynteglo®, the First Gene Therapy for People with Beta-Thalassemia Who Require Regular Red Blood Cell Transfusions

FDA approves bluebird bio's Zyntego beti-cel gene therapy for beta thalassemia

President recently sold US$96k worth of stock